enhancing drug delivery with controlled-release KCI dosage forms

customer challenge

A leading pharmaceutical manufacturer specializing in medications for hypokalemia (low potassium) sought to expand its product offerings by developing a high-dosage form for tablets and capsules.
However, their existing formulation, based on cubic potassium chloride (KCl) API, failed to achieve the required 20 mEq dosage due to limitations in particle morphology and formulation challenges.
The company needed a solution that would enable higher drug loading while ensuring controlled release and bioavailability.

Aurorium's solution

Pharma-K™ KCI - unique spherical morphology

Aurorium provided a breakthrough solution with Pharma-K™ KCl, a pharmaceutical-grade potassium chloride API featuring a unique spherical morphology. This advanced particle shape allowed for:

• more efficient and uniform coating of the active pharmaceutical ingredient (API), optimizing controlled-release properties.
• higher drug loading in tablets and capsules without compromising stability or performance.
• improved bioavailability, ensuring better therapeutic outcomes for patients.

proven benefits

1. commercial success: by leveraging Pharma-K™ KCl, the pharmaceutical manufacturer successfully launched a high-dosage product, entering a new market segment that was previously unattainable using competitive formulations. This expansion resulted in increased market share and revenue growth.
2. improved drug delivery and patient outcomes: the enhanced spherical API morphology enabled controlled-release properties, ensuring more consistent potassium levels in patients. This improvement reduced dosing frequency, enhancing patient adherence and overall treatment efficacy.
3. manufacturing efficiency: the superior particle characteristics of Pharma-K™ KCl facilitated:
   even API coating, reducing material waste and increasing process efficiency.
   optimized fluid bed processing, leading to higher productivity and lower production costs.

customer impact

innovative pharmaceutical dosage form drives commercial success

Through collaboration with Aurorium, the pharmaceutical manufacturer gained access to industry-leading expertise in API formulation and drug delivery enhancement. The ability to test the impact of particle size and shape proved instrumental in achieving a breakthrough dosage form.

future outlook

partnership with Aurorium drives innovation in drug delivery

Aurorium remains committed to supporting innovation alongside partners in pharmaceutical manufacturing. Providing next-generation healthcare solutions that enhance bioavailability, controlled release, and patient health outcomes.